1
0
0
News
Business-Profile
patentbuddy: Andreas Wilmen
BAYER PHARMA AKTIENGESELLSCHAFT, Koln, DE
Bücher
Analysen struktureller und funktioneller Komponenten des
books.google.de
Andreas Wilmen. Gießen, Seiten. 0 Rezensionen. Was andere dazu sagen - Rezension schreiben. Es wurden keine Rezensionen gefunden. Bibliografische ...
Stem Cell Engineering: Principles and Applications - Google Books
books.google.de
The potential of stem cells for healing and disease prevention in all fields of medicine is tremendous and has revolutionized the high-tech biomedical...
BMBF-Vorhaben: Zelluläre Testsysteme mit ultraphoben Oberflächen als...
books.google.de
... onkologische Forschung ; Berichtszeitraum: bis Front Cover. Janine Swifka, Andreas Wilmen. Bayer Pharma AG, pages.
Dokumente zum Namen
Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Is an...
www.scienceopen.com
Authors: Kaimei Song, Yiguang Chen, Rüdiger Göke, Andreas Wilmen, Cheryl Seidel, Alexandra Göke, Brendan Hilliard, Youhai Chen. Publication date ( Print ) ...
Veröffentlichungen allgemein
Tumor Necrosis Factor–related Apoptosis-inducing BioMedSearch
www.biomedsearch.com
By Kaimei Song, Yiguang Chen, Rüdiger Göke, Andreas Wilmen,. Cheryl Seidel, Alexandra Göke, Brendan Hilliard, and Youhai Chen. From the Department of ...
Sonstiges
CA A1 - Fusion proteins releasing relaxin and uses thereof...
patents.google.com
The present invention provides Relaxin fusion proteins, wherein a linker connects the carboxy-terminus of Relaxin with a proteinaceous half-life extending...
WO A1 - Substituierte imidazo- und trialzolopyrimidine,...
patents.google.com
Inventeurs, Stephan Siegel, Andreas Wilmen, Niels Svenstrup, Mark Jean Gnoth, ... Déposant, Bayer Schering Pharma Aktiengesellschaft , Bayer Healthcare Ag, Imidazotriazine als phosphodiesterase inhibitoren.
Antibodies capable of binding to the coagulation Factor XI and/or its...
www.patentsencyclopedia.com
... and map information provided by MapQuest, OpenStreetMap and contributors, CC-BY-SA. Patent applications by Andreas Wilmen, Koln DE.
INHIBITION OF PDE2A - Patent application
www.patentsencyclopedia.com
Inventors: Peter Ellinghaus (Wuppertal, DE) Andreas Wilmen (Koln, DE) Martin Hendrix Patent applications by Andreas Wilmen, Koln DE.
WO A3 - Substituierte imidazo- und triazolopyrimidine...
patents.google.com
Die Erfindung betrifft substituierte Imidazo- und Triazolopyrimidine und Verfahren zu ihrer Herstellung sowie ihre Verwendung zur Herstellung von Arzneimitteln...
Untitled Page
www.gccpo.org
... FREIBERG،2- Christiane OTTO،3- Lars LINDEN،4- Axel HARRENGA،5- Mark TRAUTWEIN،6- Simon GREVEN،7- Andreas WILMEN.
Roles of TNF-Related Apoptosis-Inducing Ligand in Experimental...
www.jimmunol.org
Brendan Hilliard, Andreas Wilmen, Cheryl Seidel, Tzu-Shang T. Liu, Rüdiger Göke
Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Is an...
www.ncbi.nlm.nih.gov
Kaimei Song, a Yiguang Chen, a Rüdiger Göke, a Andreas Wilmen, a Cheryl Seidel, a Alexandra Göke, a Brendan Hilliard, a and Youhai Chen a
TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE - Patent...
www.patentsencyclopedia.com
Patent application title: TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE Inventors: Stephan Siegel (Wuppertal, DE) Andreas Wilmen (Koln, DE) Niels Svenstrup
SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES - Patent...
www.patentsencyclopedia.com
Patent application title: SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES Inventors: Stephan Siegel (Berlin, DE) Andreas Wilmen (Koln, DE) Susanne Röhrig
Verwandte Suchanfragen zu Andreas Wilmen
| Rüdiger Göke Stephan Siegel Anna Wilmen |
Personen Vorname "Andreas" (97752) Name "Wilmen" (18) |
sortiert nach Relevanz / Datum